SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person [*] GORDON CARL L | 2. Date of E Requiring S (Month/Day 06/17/202 | tatement /Year) | 3. Issuer Name and Ticker or Trading Symbol <u>Compass Therapeutics, Inc.</u> [NONE] | | | | | | |
|--|--|--------------------|---|--|------------------------------------|-------------------------------|--|---|--|
| (Last) (First) (Middle) C/O COMPASS THERAPEUTICS, INC. 245 FIRST STREET, 3RD FLOOR (Street) CAMBRIDGE, MA 02142 (City) (State) (Zip) | | | 4. Relationship of Reporting Issuer (Check all applicable) X Director Officer (give title below) | 10% C |)wner (specify | File | ndividual or Jo neck Applicable Form filed Person | int/Group Filing e Line) by One Reporting by More than One | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | | |
| 1. Title of Security (Instr. 4) | | | 2. Amount of Securities Beneficially Owned (Instr. I) | | | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| Common Stock | | | 11,259,272 | Ι | | See Footnote ⁽¹⁾ | | | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | |
| Expira (Monti | 2. Date Exerc Expiration Da (Month/Day/Y | ate | 3. Title and Amount of So Underlying Derivative Se (Instr. 4) | | 4. Conver or Exer Price o | cise | 5. Ownership Form: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. | |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Derivative Security | or Indirect (I) (Instr. 5) | 5) | | |

Explanation of Responses:

1. These shares are held of record by OrbiMed Private Investments V-KA, LP ("OPI V-KA"). OrbiMed Capital GP V LLC ("OrbiMed GP V") is the general partner of OPI V-KA and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP V. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares held by OPI V-KA and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V-KA.

| /s/ Carl L. Gordon | | | | | | |
|---------------------------|--|--|--|--|--|--|
| ** Signature of Boporting | | | | | | |

Date

Signature of Reporting Person

06/23/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.